Skip to content

You are here

In Kazakhstan, registered a well-known drug for the treatment of HIV dated 14 October 2016

The Ministry of health and social development of the Republic of Kazakhstan approved the registration of well-known drug for the treatment of HIV "Trimec" (Triumeq), the correspondent with reference to the company's GSK and ViiV Healthcare.

A drug intended for the treatment of HIV infection in adults and adolescents 12 years and older weighing at least 40 pounds. This drug is representative of a new class of antiretroviral therapy based on antivirals Dolutegravir, which gives patients the opportunity to take only one tablet once a day.

Tablet contains three components, namely a standard, long-used for the treatment of HIV, combination of drugs "abacavir/lamivudine", to which was added the drug of the new generation, "dolutegravir", an integrase inhibitor.

Experts say that before using medicine that contains abacavir, an HIV-infected patient was recommended to undergo screening for the presence of genetic marker alleles HLA-B*5701. Patients with identified genetic marker have a high predisposition for hypersensitivity to abacavir.

Changed on 19 October, 2016 - 17:42
Achievements over the years of independence of RK
Targeted social assistance
Combating the worst forms of child labor
Information campaign «Safe work»
Best social projects implemented in Kazakhstan
The Republican contest «Enbekzholy»
Skills and jobs